Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Kenneth Carl Anderson, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Anderson and Mehmet Samur.
Connection Strength

3.739
  1. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23).
    View in: PubMed
    Score: 0.241
  2. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep; 2(5):468-483.
    View in: PubMed
    Score: 0.239
  3. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
    View in: PubMed
    Score: 0.236
  4. Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. 2021 01 13; 11(1):13.
    View in: PubMed
    Score: 0.235
  5. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020 11 12; 136(20):2334-2345.
    View in: PubMed
    Score: 0.232
  6. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
    View in: PubMed
    Score: 0.227
  7. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
    View in: PubMed
    Score: 0.207
  8. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
    View in: PubMed
    Score: 0.207
  9. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
    View in: PubMed
    Score: 0.194
  10. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
    View in: PubMed
    Score: 0.182
  11. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289.
    View in: PubMed
    Score: 0.180
  12. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
    View in: PubMed
    Score: 0.178
  13. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
    View in: PubMed
    Score: 0.166
  14. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.159
  15. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discov. 2021 07; 2(4):370-387.
    View in: PubMed
    Score: 0.060
  16. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919.
    View in: PubMed
    Score: 0.060
  17. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040.
    View in: PubMed
    Score: 0.059
  18. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999.
    View in: PubMed
    Score: 0.058
  19. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06.
    View in: PubMed
    Score: 0.058
  20. YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
    View in: PubMed
    Score: 0.057
  21. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835.
    View in: PubMed
    Score: 0.053
  22. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2020 01; 34(1):196-209.
    View in: PubMed
    Score: 0.052
  23. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6.
    View in: PubMed
    Score: 0.051
  24. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
    View in: PubMed
    Score: 0.051
  25. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170.
    View in: PubMed
    Score: 0.049
  26. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
    View in: PubMed
    Score: 0.049
  27. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
    View in: PubMed
    Score: 0.045
  28. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35.
    View in: PubMed
    Score: 0.044
  29. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914.
    View in: PubMed
    Score: 0.038
  30. Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
    View in: PubMed
    Score: 0.038
  31. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.